Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|October 16, 2012
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potentialPatricia M LoRusso, Sarina A Piha-Paul, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignanciesBahram Forouzesh, Manuel Hidalgo, Quincy Chu, et al.
Investigational New Drugs|August 25, 2012
Metabolism of patupilone in patients with advanced solid tumor malignanciesKevin R Kelly, Markus Zollinger, Frédéric Lozac'h, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2014
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumorsMonica Mita, Michael Gordon, Lee Rosen, et al.
Molecular Cancer Therapeutics|January 12, 2011
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trialApostolia-Maria Tsimberidou, Chris H M Takimoto, Stacy Moulder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsPamela N Munster, Carolyn D Britten, Monica Mita, et al.
American Journal of Clinical Oncology|December 13, 2002
Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcomaXavier Pivot, Christine Chevreau, Didier Cupissol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesSanjay Goel, Alain C Mita, Monica Mita, et al.
Plos One|September 19, 2019
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptomsEdward Wolin, Alain Mita, Amit Mahipal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Pageof 6